ABCG2 and cancer: In cancer patients, our tracer is not expected to affect the distribution of BCRP-mediated anticancer drugs such as mitoxantrone [25], because here we show that fluciclovine does not inhibit the transport of the BCRP-specific substrate [3H]estrone-3-sulfate (ES, Figure 4e and Table 1).